Literature DB >> 14975752

Basis for fusion inhibition by peptides: analysis of the heptad repeat regions of the fusion proteins from Nipah and Hendra viruses, newly emergent zoonotic paramyxoviruses.

Yanhui Xu1, Shan Gao, David K Cole, Junjie Zhu, Nan Su, Hui Wang, George F Gao, Zihe Rao.   

Abstract

Nipah virus (NiV) and Hendra virus (HeV) are novel zoonotic members of the Paramyxoviridae family and are the prototypes for a newly designated genus, Genus Henipavirus. Recent studies have shown that paramyxovirus might adopt a similar mechanism of virus fusion-entry. Under this mechanism, the two highly conserved heptad repeat (HR) regions, HR1 and HR2, in the fusion (F) protein, seem to show characteristic structure in the fusion core: the formation of a 6-helix coiled-coil bundle. The three HR1s form the alpha-helix coiled-coil surrounded by three HR2s. In this study, the two HR regions of NiV or HeV were expressed in an Escherichia coli system as a single chain and the results do show that HR1 and HR2 interact with each other in both NiV and HeV and form typical 6-helix coiled-coil bundles. This provides the molecular basis of HR2 inhibition to NiV and HeV fusion as observed in an earlier report.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14975752     DOI: 10.1016/j.bbrc.2004.01.115

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.

Authors:  Zhonghua Liu; Mei Shan; Li Li; Lu Lu; Shu Meng; Cheng Chen; Yuxian He; Shibo Jiang; Linqi Zhang
Journal:  J Biol Chem       Date:  2010-11-23       Impact factor: 5.157

2.  Inhibition of hendra virus fusion.

Authors:  M Porotto; L Doctor; P Carta; M Fornabaio; O Greengard; G E Kellogg; A Moscona
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 3.  HIV-1 gp41 heptad repeat 2 (HR2) possesses an amino acid domain that resembles the allergen domain in Aspergillus fumigatus Asp f1 protein: review, hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2007-03-01       Impact factor: 2.332

Review 4.  Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.

Authors:  Lu Lu; Fei Yu; Lifeng Cai; Asim K Debnath; Shibo Jiang
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

5.  Cloning, expression, purification, crystallization and preliminary crystallographic study of the protein module (BIV2-Helix) in the fusion core of bovine immunodeficiency-like virus (BIV) gp40.

Authors:  Xiaodong Zhao; Ming Li; Yanhui Xu; Zhiyong Lou; Zhaohui Meng; Shu Li; Bo Tian; George F Gao; Zihe Rao
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-02-01

6.  Molecular determinants of antiviral potency of paramyxovirus entry inhibitors.

Authors:  M Porotto; P Carta; Y Deng; G E Kellogg; M Whitt; M Lu; B A Mungall; A Moscona
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

7.  Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein.

Authors:  Katharine N Bossart; Bruce A Mungall; Gary Crameri; Lin-Fa Wang; Bryan T Eaton; Christopher C Broder
Journal:  Virol J       Date:  2005-07-18       Impact factor: 4.099

8.  Targeted strategies for henipavirus therapeutics.

Authors:  Katharine N Bossart; John Bingham; Deborah Middleton
Journal:  Open Virol J       Date:  2007-09-28

Review 9.  Influenza A virus entry inhibitors targeting the hemagglutinin.

Authors:  Jie Yang; Minmin Li; Xintian Shen; Shuwen Liu
Journal:  Viruses       Date:  2013-01-22       Impact factor: 5.048

10.  Novel anti-HIV peptides containing multiple copies of artificially designed heptad repeat motifs.

Authors:  Weiguo Shi; Zhi Qi; Chungen Pan; Na Xue; Asim K Debnath; Jiankun Qie; Shibo Jiang; Keliang Liu
Journal:  Biochem Biophys Res Commun       Date:  2008-08-03       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.